✦ LIBER ✦

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone

✍ Scribed by Martin Hjorth; Louise Hellquist; Erik Holmberg; Bengt Magnusson; Stig Rödjer; Jan Westin; for the Myeloma Group of Western Sweden

Book ID: 114712003
Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 633 KB
Volume: 74
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1990.tb02564.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib plus Melphalan and Prednisone

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

✍ San Miguel, Jesús F.; Schlag, Rudolf; Khuageva, Nuriet K.; Dimopoulos, Meletios 📂 Article 📅 2008 🏛 Massachusetts Medical Society 🌐 English ⚖ 356 KB

Bortezomib-Melphalan-Prednisone-Thalidom

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

✍ Palumbo, A.; Bringhen, S.; Larocca, A.; Rossi, D.; Di Raimondo, F.; Magarotto, V 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 253 KB

Randomized comparison of dexamethasone c

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma

✍ J. M. Hernández; R. García-Sanz; E. Golvano; J. Bladé; J. Fernandez-Calvo; J. Tr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

PSY19 THE COST-EFFECTIVENESS OF BORTEZOM

PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

✍ S.T. Wang; H. Huang; A. Ba-mancini; H. Shi; K. Chen; C. Korves; R. Dhawan; A. Ca 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Comparison of melphalan and prednisone w

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479

✍ Martin M. Oken; David P. Harrington; Neil Abramson; Robert A. Kyle; William Knos 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## METHODS. Four hundred seventy-nine previously untreated patients with multiple myeloma from 23 ECOG institutions were enrolled. Treatment, assigned by ran-1 The Virginia Piper Cancer Institute and the Unidomization, consisted of either 4-week cycles of MP or 5-week cycles of VBCMP.

The use of low-dose prednisone and melph

The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma

✍ Cuttner, Janet ;Wasserman, L. R. ;Martz, Georg ;Sonntag, Roland W. ;Kyle, Robert 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 416 KB

## Abstract A study was designed to evaluate the effectiveness of prednisone therapy in poor‐risk patients with multiple myeloma. Patients were treated with melphalan alone or in combination with prednisone at doses of either 0.6 mg/kg or 0.3 mg/ kg. The group of patients receiving melphalan and pr